Brief: Satsuma Pharmaceuticals Announces Topline Results From Summit Phase 3 Trial Of STS101
14/11/2022 13:21
Nov 14 (Reuters) - Satsuma Pharmaceuticals Inc STSA.O :
* SATSUMA PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM
SUMMIT
PHASE 3 TRIAL OF STS101 FOR THE ACUTE TREATMENT OF MIGRAINE
* SATSUMA PHARMA - STS101 WAS NOT STATISTICALLY SUPERIOR TO
PLACEBO AT TWO HOURS POST-ADMINISTRATION ON CO-PRIMARY ENDPOINTS
IN STUDY
* SATSUMA PHARMACEUTICALS INC - STS101 DEMONSTRATED A
FAVORABLE
SAFETY AND TOLERABILITY PROFILE, CONSISTENT WITH CLINICAL TRIAL
EXPERIENCE TO DATE
* SATSUMA PHARMACEUTICALS -BELIEVES RESULTS FROM STS101
PHASE 1
PK & ASCEND PHASE 3 LONG-TERM, OPEN-LABEL SAFETY TRIALS TO
SUPPORT NDA FILING, APPROVAL
* SATSUMA PHARMACEUTICALS INC - DOES NOT PLAN TO INVEST IN
COMMERCIALIZING STS101 AND WILL ACTIVELY EXPLORE ALTERNATIVES
Source text for Eikon: ID:nGNX98MGnH
Further company coverage: STSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Satsuma Pharmaceuticals
See all newsBrief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon